Neurofibromatosis Clinical Trial
Official title:
Pilot Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
The purpose of this Pilot Study is to determine if NF1 patients with plexiform neurofibromas treated with Tasgina® respond to therapy.
This is an open-label Pilot Study to determine the efficacy of Tasigna® in adults with neurofibromatosis (NF1) and plexiform neurofibromas with the secondary goals of determining the toxicity, and tumor markers in this genetically defined population. The rationale for this study arises from the response of human and murine NF1 cells to Tasigna® in vitro and the clinical response in NF1 patients with plexiform neurofibromas using the similar drug, Gleevec®. Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated. Subjects will have his/her dose increased as tolerated dose during the first three months of therapy. The maximum targeted dose is 400mg twice daily. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00754780 -
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
|
Phase 2 | |
Completed |
NCT00589784 -
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
|
Phase 2 | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Completed |
NCT01673009 -
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
|
Phase 2 | |
Recruiting |
NCT00598351 -
Natural History Study of Patients With Neurofibromatosis Type 2
|
||
Completed |
NCT02298270 -
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
|
N/A | |
Terminated |
NCT01402817 -
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
|
Phase 2 | |
Completed |
NCT02101736 -
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
|
Phase 2 | |
Completed |
NCT01633008 -
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain
|
Early Phase 1 | |
Terminated |
NCT04461886 -
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
|
Phase 3 | |
Completed |
NCT02435628 -
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF
|
N/A | |
Active, not recruiting |
NCT01140360 -
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
|
Phase 1/Phase 2 | |
Completed |
NCT02211768 -
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
|
Phase 1 | |
Completed |
NCT00508235 -
Quality of Friendships in Children With Neurofibromatosis
|
N/A | |
Completed |
NCT01639950 -
Validating Pain Scales in Children and Young Adults
|